 SEATTLE--BUSINESS WIRE--Silverback Therapeutics, Inc. Nasdaq: SBTX Silverback, a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the appointment of Maria Koehler, M.D., Ph.D. to Silverbacks Board of Directors. On behalf of the board of directors and senior management team at 